Ignite Creation Date:
2024-05-06 @ 3:31 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04654026
Status:
UNKNOWN
Last Update Posted:
2021-02-08
First Post:
2020-10-11
Brief Title:
the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
Sponsor:
Shenzhen Second Peoples Hospital
Organization:
Shenzhen Second Peoples Hospital
Study Overview
Official Title:
Single-center Prospective Controlled Study of the Safety and Efficacy of Aspirin and Clopidogrel in Ischemic Cardiovascular and Cerebrovascular Patients Complications With CAA
Status:
UNKNOWN
Status Verified Date:
2020-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ischemic cardiovascular and cerebrovascular diseases are the main causes of death among people Antiplatelet threrapy is very important for patients to prevent ischemic cardiovascular and cerebrovascular diseasesIschemic cardiovascular patients of cerebral amyloid angiopathy CAA patients is as high as 20 aspirin and clopidogrel is applied to prevent or treat the patient with CAA is controversial there is no valid evidence of CAA crowd is safe to use of antiplatelet drugs but progress in clinical treatment is usually based on patient condition for antiplatelet agents to prevent the occurrence of adverse events such as blood clotsTherefore this study is intended to be a single-center prospective study of patients with ischemic cardiovascular and cerebrovascular diseases taking aspirin and clopidogrel to determine whether the patients are combined with CAA and to conduct a follow-up study for 12 months after team inclusion1 The prevalence rate and gene spectrum of ischemic cardiovascular and cerebrovascular diseases among CAA patients enrolled in our hospital were analyzed2 To explore the correlation between aspirin and clopidogrel drug genes and blood drug concentrations and diseases in patients with ischemic cardiovascular and cerebrovascular diseases complicated with CAA3 To evaluate the efficacy and safety of aspirin and clopidogrel in patients with ischemic cardiovascular and cerebrovascular diseases who combined with CAA
Detailed Description:
This project intends to observation of bleeding the application of antiplatelet in patients with CAA so as to provide effective clinical evidence for the further application of clopidogrel and aspirin in patients with CAA in the future and to provide reference basis for the accurate formulation of clinical treatment plans and the balance of health risks brought by adverse bleeding reactions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None